Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
nL-ATN1-002 in DRPLA
NCT06706388Phase 2Active, not recruiting
- Sponsor
- n-Lorem Foundation
- Start
- Feb 2024
- Primary completion
- Feb 2027
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
A Phase 2 trial of nL-ATN1-002 in dentatorubral-pallidoluysian atrophy (DRPLA), sponsored by n-Lorem Foundation. Started Feb 2024; status: active, not recruiting.
02
Drugs
nL-ATN1-002
03
Conditions
dentatorubral-pallidoluysian atrophy (DRPLA)
Beyond the preview
Go deeper on NCT06706388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06706388.